Millions of Americans with medical conditions spend years waiting for breakthrough treatments. Today's guest is making extraordinary advances in cancer treatment to significantly improve outcomes.Today we're sitting down with Dr. Marc Hedrick, President and CEO at Plus Therapeutics whose stock trades under the symbol PSTV. Previously, Dr. Hedrick served in a number of executive leadership roles, including President, CEO and Director of Cytori Therapeutics, and President and CEO of STEM Source. He's a trained general vascular and plastic surgeon, and former Associate Professor of Surgery and Pediatrics at UCLA. He also served as co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA. Dr. Hedrick received his MD from University of Texas Southwestern Medical School Dallas, and an MBA from the Anderson School at UCLA in 2005. We talked about his company's incredible new technology that is revolutionizing how some cancers can be treated. Highlights:Marc describes his background, and path to the medical field (2:52)How Plus Therapeutics approaches their work to change outcomes for debilitating diseases (3:34)How Plus Therapeutics targeted treatment differs from traditional radiotherapy (5:19)Marc breaks down how the company chooses what types of cancer to develop treatments for (6:11)How Plus Therapeutics is driving innovation (7:39)What treatments their distinctive drugs can be used for and how they work (9:44)Plus Therapeutics partnerships, and what the company looks for in a partner (12:16)How the company managed challenges through the COVID-19 pandemic (13:47)Competition in the CNS space, and the challenges Plus Therapeutics faced introducing a new treatment (15:18)Funding, and the company's unique capitalization strategy (16:33)The competitive landscape (18:32)Plus Therapeutics leadership team, and value of culture (20:16)Locational benefits, and the entrepreneurial ecosystem in Texas (21:42)Marc's predictions on the future of the radiotherapy industry (22:59)What investors might not understand about this company (24:42)Links:ICR TwitterICR LinkedInICR WebsiteMarc Hedrick on LinkedInPlus Therapeutics on LinkedInPlus Therapeutics WebsiteFeedback:If you have questions about the show, or have a topic in mind you'd like discussed in future episodes, email our producer, [email protected].

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related